~~<i id='EC87B1BE1C'><strike id='EC87B1BE1C'><tt id='EC87B1BE1C'><pre id='EC87B1BE1C'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：leisure time 2025-09-28 05:28:34 Page View：9

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In rare move, senator releases unverified FBI source report alleging Biden bribe
Next article： At least 13 dead in Texas as scorching temps continue

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Boston's new lab space is opening empty

MichaelDwyer/APAroundthistimethreeyearsago,whilemostofus navigatedpandemiclife,realestatedevelopersa

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Amid AI frenzy, a top HHS official's quest to create safeguards

MickyTripathiOfficeoftheNationalCoordinatorforHealthInformationTechnologyMickyTripathiisequalpartsex